Search results
Results from the WOW.Com Content Network
Amount: $160 million Bank of America took a hit owing to its 2008 acquisition of Merrill Lynch in 2013, when Merrill Lynch agreed to pay $160 million to settle a class-action racial discrimination ...
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
The following is a list of the 21 largest civil settlements, reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2017, ordered by the size of the total civil settlement. Some of these matters also resolved criminal fines and penalties, listed in parentheses, but these amounts are not considered when ...
The settlement includes those who received erroneous overdraft fees in their checking accounts, misapplied payments in their auto loans and even negligent foreclosure proceedings.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
MuscleTech is a brand of dietary supplements, marketed by Iovate Health Sciences Inc., which includes Hydroxycut. It was owned by Canadian company Kerr Holdings which was acquired by the Xiwang Foodstuffs Company, a Chinese company, for $584 million in 2016.
A recent settlement from vape maker Juul is giving out huge amounts of money, and people are shocked. Check out the details. People Are Getting Huge Sums of Money From $300 Million Juul Class ...
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...